ZA978536B - Nucleic acid constructs containing hybrid promoters for use in gene therapy. - Google Patents

Nucleic acid constructs containing hybrid promoters for use in gene therapy.

Info

Publication number
ZA978536B
ZA978536B ZA9708536A ZA978536A ZA978536B ZA 978536 B ZA978536 B ZA 978536B ZA 9708536 A ZA9708536 A ZA 9708536A ZA 978536 A ZA978536 A ZA 978536A ZA 978536 B ZA978536 B ZA 978536B
Authority
ZA
South Africa
Prior art keywords
nucleic acid
gene therapy
acid constructs
constructs containing
hybrid promoters
Prior art date
Application number
ZA9708536A
Other languages
English (en)
Inventor
Klaus-Heinrich Seifart
Rolf Mueller
Hans-Harald Sedlacek
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA978536B publication Critical patent/ZA978536B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
ZA9708536A 1996-09-24 1997-09-23 Nucleic acid constructs containing hybrid promoters for use in gene therapy. ZA978536B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19639103A DE19639103A1 (de) 1996-09-24 1996-09-24 Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen

Publications (1)

Publication Number Publication Date
ZA978536B true ZA978536B (en) 1998-04-17

Family

ID=7806676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9708536A ZA978536B (en) 1996-09-24 1997-09-23 Nucleic acid constructs containing hybrid promoters for use in gene therapy.

Country Status (10)

Country Link
US (2) US6576758B1 (xx)
EP (1) EP0848063A3 (xx)
JP (1) JPH10108687A (xx)
KR (1) KR19980025142A (xx)
AR (1) AR008847A1 (xx)
AU (1) AU722354B2 (xx)
BR (1) BR9704857A (xx)
CA (1) CA2211008A1 (xx)
DE (1) DE19639103A1 (xx)
ZA (1) ZA978536B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
IL132446A0 (en) * 1999-10-18 2001-03-19 Genena Ltd A method for establishing connections between genes
AU2001237256A1 (en) * 2000-03-08 2001-09-17 Neurosearch A/S A method of sensitising endothelial cells to prodrugs
CA2434543A1 (en) * 2001-01-12 2002-07-18 Sbarro Institute For Cancer Research And Molecular Medicine Inhibition of pathological angiogenesis in vivo
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69101032T2 (de) 1990-07-03 1994-08-11 Kuraray Co Katalysator und Verfahren zur Herstellung von ungesättigten Estern.
US5654168A (en) * 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0705334A1 (en) * 1993-06-14 1996-04-10 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE4429710A1 (de) 1994-08-22 1996-02-29 Jun Alexander Faller Verfahren und Vorrichtung zum Umschlagen von Ladung
WO1996006938A1 (de) 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DK0807183T3 (da) 1994-08-26 2001-03-05 Aventis Pharma Gmbh Genterapi af sygdomme, der fremkaldes af immunsystemet, ved hjælp af et cellespecifikt aktivt stof, der reguleres af cellec
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
DE19710643A1 (de) * 1997-03-14 1998-09-17 Hoechst Ag Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie

Also Published As

Publication number Publication date
EP0848063A2 (en) 1998-06-17
KR19980025142A (ko) 1998-07-06
AR008847A1 (es) 2000-02-23
DE19639103A1 (de) 1998-03-26
BR9704857A (pt) 1998-10-27
US6576758B1 (en) 2003-06-10
EP0848063A3 (en) 2002-01-02
US20030187245A1 (en) 2003-10-02
AU722354B2 (en) 2000-07-27
AU3919997A (en) 1998-03-26
JPH10108687A (ja) 1998-04-28
CA2211008A1 (en) 1998-03-24

Similar Documents

Publication Publication Date Title
ZA978536B (en) Nucleic acid constructs containing hybrid promoters for use in gene therapy.
GB9620769D0 (en) Nucleic acid sequencing
IL123172A0 (en) Dna constructs
HK1012398A1 (en) Phosphonomonoester nucleic acids, methods for their preparation and their use
AU7401394A (en) In vivo nucleic acid hybridization method
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
HK1000786A1 (en) Dna constructs for endogenous gene activation and expression modification.
AU4065997A (en) Non-viral vehicles for use in gene transfer
EP0744894A4 (en) SELF-COMPOSING MULTIMERIC NUCLEIC ACID
ZA964136B (en) Catalytic DNA.
AU6591798A (en) Nucleic acid catalysts
AU3595493A (en) Method for nucleic acid hybridization using single-stranded DNA binding protein
HUP0001937A3 (en) Compounds, preparation and use for transferring nucleic acids into cells
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
HUP0104681A3 (en) Human hybrid host cell for mammalian gene expression
EP0579360A3 (en) Gene for a hyperthermophilic alpha-amylase.
ZA972837B (en) Spray-dried microparticles as therapeutic vehicles for use in gene therapy.
IL130886A0 (en) Nucleic acid sequencing
ZA973802B (en) Nucleic acid constructs containing genes encoding transport signals.
AU3762699A (en) (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
GB9917875D0 (en) Nucleic acid constructs
AU2114899A (en) Nucleotide expression systems with reduced immunogenicity for use in gene therapy
AU2750197A (en) Dna replication-regulating genes
AU3571797A (en) Nucleic acid molecule for enhancing gene expression
AU1029099A (en) Transfection system for the transfer of nucleic acids into cells